subscribe
 

Collaboration to improve the risk profiling of cancer patients

30th April 2018


Protagen and Gustave Roussy have announced the start of a collaboration to use Protagen's SeroTag technology to help identify biomarkers that predict and monitor immune-related adverse events (irAEs) in cancer patients treated with checkpoint inhibitors.

Checkpoint inhibitors offer enormous potential for the treatment of many cancer indications, including melanoma and renal cell carcinoma. Yet, only a subset of patients respond favourably to treatment and it is not currently possible to predict which patients will benefit from therapy. In addition, checkpoint inhibitors can also trigger (often severe) irAEs, which has led to the FDA halting clinical trials in the past. Through this new collaboration, Protagen and Gustave Roussy will use Protagen's immune system profiling platform, SeroTag, to monitor patients, detect irAEs and ultimately conduct comprehensive risk profiling for those undergoing cancer immunotherapy. This project is part of the ongoing Gustave Roussy Immunotherapy Program (GRIP), which aims at developing immunotherapy access and best practice.

Dr. Aurelien Marabelle, clinical director of the Gustave Roussy Immunotherapy Program commented: "Although immunotherapies like checkpoint inhibitors have shown great promise for treating those suffering from cancer, response rates for these therapies are still low (often around 10-20%). In addition, our efforts to improve therapeutic outcomes via the implementation of combination therapies can increase the risk of the patient developing debilitating and sometimes fatal irAEs. It is therefore vital that we try to understand more about the immunological responses patients are exhibiting to cancer, both before and during therapy. Using the SeroTag platform will enable us to ask these questions, and we very much look forward to this collaboration."





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe